These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26542504)

  • 1. Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.
    Reed SD; Neilson MP; Gardner M; Li Y; Briggs AH; Polsky DE; Graham FL; Bowers MT; Paul SC; Granger BB; Schulman KA; Whellan DJ; Riegel B; Levy WC
    Am Heart J; 2015 Nov; 170(5):951-60. PubMed ID: 26542504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions.
    Reed SD; Li Y; Kamble S; Polsky D; Graham FL; Bowers MT; Samsa GP; Paul S; Schulman KA; Whellan DJ; Riegel BJ
    Circ Cardiovasc Qual Outcomes; 2012 Jan; 5(1):113-9. PubMed ID: 22147884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care).
    Maru S; Byrnes J; Carrington MJ; Chan YK; Thompson DR; Stewart S; Scuffham PA;
    Int J Cardiol; 2015 Dec; 201():368-75. PubMed ID: 26310979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial.
    Martinson M; Bharmi R; Dalal N; Abraham WT; Adamson PB
    Eur J Heart Fail; 2017 May; 19(5):652-660. PubMed ID: 27647784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of supervised exercise therapy in heart failure patients.
    Kühr EM; Ribeiro RA; Rohde LE; Polanczyk CA
    Value Health; 2011; 14(5 Suppl 1):S100-7. PubMed ID: 21839879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure disease management programs: a cost-effectiveness analysis.
    Chan DC; Heidenreich PA; Weinstein MC; Fonarow GC
    Am Heart J; 2008 Feb; 155(2):332-8. PubMed ID: 18215605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
    Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
    Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure.
    Postmus D; Pari AA; Jaarsma T; Luttik ML; van Veldhuisen DJ; Hillege HL; Buskens E
    Am Heart J; 2011 Dec; 162(6):1096-104. PubMed ID: 22137084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
    Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
    Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cost-effectiveness of disease management in systolic heart failure.
    Miller G; Randolph S; Forkner E; Smith B; Galbreath AD
    Med Decis Making; 2009; 29(3):325-33. PubMed ID: 19147835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.
    Caro JJ; Guo S; Ward A; Chalil S; Malik F; Leyva F
    Curr Med Res Opin; 2006 Jun; 22(6):1171-9. PubMed ID: 16846550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
    Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
    Banz K;
    Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure management: optimal health care delivery programs.
    Moser DK
    Annu Rev Nurs Res; 2000; 18():91-126. PubMed ID: 10918933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of telehealth interventions for chronic heart failure patients: a literature review.
    Grustam AS; Severens JL; van Nijnatten J; Koymans R; Vrijhoef HJ
    Int J Technol Assess Health Care; 2014 Jan; 30(1):59-68. PubMed ID: 24495581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease Management.
    Cao Q; Buskens E; Feenstra T; Jaarsma T; Hillege H; Postmus D
    Med Decis Making; 2016 Jan; 36(1):59-71. PubMed ID: 26174352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.